A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

This Phase 1 study tests [225Ac]-AZD2284, a new type of radioactive drug that delivers radiation directly to prostate cancer cells. It targets a protein called PSMA that is found on the surface of many prostate cancer cells, aiming to kill those cells with minimal harm to surrounding tissue. **You may be eligible if:** - You have a confirmed diagnosis of prostate cancer (adenocarcinoma or neuroendocrine type) - Your cancer has spread and no longer responds to hormone therapy (castration-resistant) - You have had prior hormone suppression therapy (surgery or medication) - You are in good physical condition (ECOG performance status 0 or 1) - Your PSMA levels in the tumor are high enough (confirmed by scan) **You may NOT be eligible if:** - Your cancer has not yet become castration-resistant - You have not had prior hormone therapy - Your overall health is too poor to tolerate the treatment - You have had prior treatment with certain radioactive therapies - You have significant kidney, liver, or bone marrow problems Talk to your doctor to see if this trial is right for you.